Dr. Peter Hosein, MD

Leader of The Pancreatic Cancer and GI Cancer Program At The Sylvester Comprehensive Cancer Center and Associate Professor of Clinical Medicine at The University of Miami Health System

Dr. Peter Hosein, Associate Professor of Clinical Oncology and co-leader of the Gastrointestinal Cancers Group at the Sylvester Comprehensive Cancer Center. Dr. Hosein is a clinical researcher focused on gastrointestinal cancers. He has been the principal investigator for multiple clinical trials for patients with liver and pancreatic cancers conducted at the Sylvester Comprehensive Cancer Center of the University of Miami Health System.  He has participated in studies that has led to breakthroughs such as the early trials of nab-paclitaxel (Abraxane) and olaparib (Lynparza) for pancreatic cancer. Dr. Hosein is known for providing compassionate care to patients with pancreatic cancer as part of a strong multi-disciplinary team devoted to delivering excellent care of patients with difficult cancers.

He has been the principal investigator for multiple phase I and II clinical trials for patients with liver and pancreatic cancers conducted at the Sylvester Comprehensive Cancer Center. He has also participated as a co-investigator in national phase III clinical trials in pancreatic and colorectal cancers. His primary research interest is in neoadjuvant therapy for patients with localized pancreatic cancer, and novel therapies for metastatic pancreatic cancer.

Education and Credentials

University of the West Indies Faculty of Medicine, Trinidad and Tobago (2001)

Jackson Memorial Hospital Division of Hematology/Oncology (2010)

Hematology
American Board of Internal Medicine

Master Oncology
American Board of Internal Medicine

Internal Medicine
American Board of Internal Medicine

Sampling of Many Studies Related To Pancreatic Cancer Involving Dr. Peter J. Hosein

https://pubmed.ncbi.nlm.nih.gov/34233640/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955014/
https://academic.oup.com/jnci/article/111/8/782/5488951
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848048/
https://link.springer.com/article/10.1186/s12885-021-08474-4
https://journals.lww.com/pancreasjournal/Abstract/2019/07000/Does_Neoadjuvant_Chemotherapy_Change_the_Role_of
https://journals.lww.com/ajg/Fulltext/2018/10001/High_Rate_of_Actionable_Variants_Identifed_by